House prepares to take up Senate version of "Big, Beautiful Bill" as some GOP lawmakers express skepticism
The measure narrowly survived the Senate after a marathon session ended with Vice President JD Vance casting the tie-breaking vote Tuesday.
The House Rules Committee was quick to take up the legislation Tuesday afternoon, hoping to tee it up for a vote on the House floor by the morning.
But first GOP leaders will have to win over Republicans who are opposed to the changes the Senate made to the bill that the House passed in May. The Senate's steeper cuts to Medicaid are likely to irritate moderates while the higher price tag could alienate conservatives. The Congressional Budget Office estimated that the Senate bill would add $3.3 trillion to federal deficits over the next 10 years.
"We got more work to do, but it's going to get done," House Speaker Mike Johnson, a Louisiana Republican, told reporters as Congress scrambles to meet a self-imposed Fourth of July deadline to get the bill to Mr. Trump.
Johnson also said he expected the Rules Committee meeting to last late into the night. Democrats said they planned to force debate in the committee on hundreds of amendments to drag out the process.
House Majority Whip Tom Emmer, a Minnesota Republican, said the lower chamber would vote on the Senate bill as-is. If the House makes changes of its own, the Senate would need to sign off on those as well, creating another hurdle to final passage. Mr. Trump has threatened to support primary challengers to Republicans who vote against the bill.
Republican Rep. Chip Roy of Texas is a member of the Rules Committee who has been highly critical of both versions but ultimately voted to pass the House bill in May, which passed by one vote. He said Tuesday afternoon he was not inclined to the support the Senate version.
"I think the odds are a hell of a lot lower than they were even 48 hours ago or 72 hours ago based on the deal-cutting that I just saw," Roy said about hitting Friday's deadline.
Republican Rep. Ralph Norman of South Carolina, another member on the panel who also eventually folded and supported the House bill, called on the lower chamber to go back to the drawing board.
"What the Senate did is unconscionable," Norman said at the House Rules meeting. "What the Senate did, I'll vote against it here and I'll vote against it on the floor."
Republican Rep. Andy Ogles of Tennessee called the Senate bill a "dud." Rep. Andy Biggs of Arizona said it's hard to see how the bill passes "as-is" because "there's some amazingly bad stuff" in the measure.
Johnson acknowledged that the Senate "went a little further" than many House GOP members would have preferred and expected that the Rules Committee would be working late into the night to prepare it for a floor vote.
Jaala Brown and Lucy Curtis-Cherry contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
24 minutes ago
- Associated Press
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ('Sarepta' or the 'Company') (NASDAQ: SRPT) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) ELEVIDYS posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (iv) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. On March 18, 2025, Sarepta issued a safety update on ELEVIDYS announcing that a patient had died following treatment with ELEVIDYS. On this news, Sarepta's stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025. Then, on April 4, 2025, Sarepta disclosed that European Union member country authorities had requested that the independent data monitoring committee meet to review death announced on March 18, 2025. Sarepta simultaneously halted recruitment and dosing in some of the ELEVIDYS clinical studies. On this news, Sarepta's stock price fell $4.18 per share, or 7.13%, to close at $54.43 per share on April 4, 2025. Next, on June 15, 2025, Sarepta disclosed a second patient had died of acute liver failure following treatment with ELEVIDYS. The Company announced it was suspending shipments of ELEVIDYS for non-ambulatory patients while Sarepta took time to evaluate trial regimens and discussed findings with regulatory authorities. Sarepta also revealed that it was pausing dosing in one of its ELEVIDYS clinical studies. On this news, Sarepta's stock price fell $15.24 per share, or 42.12%, to close at $20.91 per share on June 15, 2025. Finally, on June 24, 2025, the United States Food and Drug Administration ('FDA') issued a Safety Communication announcing it had received reports of two deaths and was investigating the risk of acute liver failure with serious outcomes following treatment with ELEVIDYS. The communication noted that the FDA was evaluating the need for further regulatory action. On this news, Sarepta's stock price fell $1.52 per share, or 8.01%, to close at $17.46 per share on June 25, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Sarepta's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Sarepta Therapeutics class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at
New York Times
29 minutes ago
- New York Times
How Europe Got Stuck Between Xi's China and Trump's America
It once looked to many as if President Trump could be a reason for Europe and China to bring their economies closer. His planned tariffs did little to distinguish the European Union, a longtime ally of the United States, from China, the principal challenger to American primacy. It hasn't turned out that way. Instead, the European Union finds itself in a geopolitical chokehold between the world's two largest economies. In Brussels, officials are trying to secure a rough trade deal with their American counterparts before Mr. Trump hits the bloc with high, across-the-board tariffs that could clobber the bloc's economy. At the same time, European Union policymakers are trying to prod their counterparts in Beijing to stop supporting Russia, to stop helping Chinese industry with so much state money and to slow the flow of cheap goods into the European Union. But at a moment of upheaval in the global trading system, the bloc also needs to keep its relationship with China, the world's leading manufacturing superpower, on a relatively stable footing. Leaders from the European Union are scheduled to be in Beijing for a summit in late July, plans for which have been in flux. Hopes for the gathering are low. Even as China pushes the idea that Mr. Trump's hostility to multilateral trade is prodding Europe into its arms, Europe's problems with China are only growing. 'There is no China card for Europe,' said Liana Fix, a fellow for Europe at the Council on Foreign Relations. Want all of The Times? Subscribe.
Yahoo
31 minutes ago
- Yahoo
What to Expect From Bitcoin and Crypto Markets in the 2nd Half of 2025
Bitcoin treasury companies are becoming a dominant force in the crypto market, a trend that analysts expect to continue in the second half of 2025. More spot crypto ETFs and crypto-related IPOs are also right around the corner. Ether has lagged behind bitcoin and many smaller crypto assets over the past few years, but some experts say it's not time to give up on the world's second-largest crypto asset just been a tremendous year so far for bitcoin and the crypto market. Cryptocurrencies have gained greater acceptance in Washington, with President Donald Trump establishing a strategic bitcoin reserve and the Senate passing the GENIUS Act. They've also found favor with traditional finance; spot bitcoin exchange-traded fund net inflows in 2025 have totaled $14.4 billion through July 3, according to data from Farside Investors. Bitcoin (BTCUSD) has gained about 15% since the start of year, outpacing the S&P 500's rise of 7%. It isn't far from the all-time high of near $112,000 set in May, edging closer to the bullish year-end targets analysts set at the start of the year. Here's what crypto investors will be watching for in the second half of the year. So-called bitcoin treasury companies have been the talk of the town in 2025. A bitcoin treasury company is a business that holds a substantial portion of its reserve assets in bitcoin, often as an inflation hedge or in anticipation of bitcoin's development as a global, apolitical reserve asset. Some companies, like Michael Saylor's Strategy (MSTR), take it a step further by issuing shares or debt to accumulate bitcoin. Strategy (formerly MicroStrategy) has been at this for years, but there are several new players entering the arena, including Metaplanet and Twenty One. There are now an estimated 135 public companies that hold bitcoin as a reserve asset. "The latter half of 2025 will mark a pivotal moment for bitcoin's adoption as a treasury asset, driven by a convergence of global market trends, shifting corporate strategies, and institutional validation,' Stephen Cole, who is the co-founder and CEO of bitcoin treasury solution provider Castle, told Investopedia. "We're already seeing bitcoin treasury companies emerge in every major global capital market and [I] expect that trend to continue," he said. Cole expects larger companies, including well-known tech giants, to begin establishing bitcoin positions and defining their allocation strategies by the end of the year. 'For (small and medium sized businesses) and large corporations alike, the question of whether to acquire bitcoin is quickly going from if to when,' Cole added. Some have wondered if bitcoin treasury companies will sap demand for smaller, more volatile altcoins. 'Demand for altcoins has historically stemmed from two main sources: (1) beta exposure to bitcoin, and (2) differentiated use cases that bitcoin's blockchain doesn't fulfill,' David Lawant, Head of Research at FalconX, told Investopedia. 'What we're seeing now is that bitcoin treasury companies and broader access to instruments like options can meet that first demand more efficiently and with less friction.' However, Lawant says bitcoin treasuries only satisfy some of the criteria that drive demand for altcoins. He also cautioned that 'the cycle is likely far from over,' and in his view, there is still time for certain types of alternative crypto assets to shine. 'Altcoins with a strong and distinct fundamental value proposition still have plenty of room to perform,' said Lawant. 'Regulatory shifts such as the crypto market structure bill and a more permissive stance toward decentralized finance (DeFi) experimentation could unlock powerful new trends.' Of course, bitcoin treasury companies aren't the only way to gain exposure to bitcoin and other crypto assets via public markets. Spot ETFs for bitcoin and ether already exist, and according to Bloomberg analyst James Seyffart, similar products could be on the way for other digital assets. Tweaks to existing ETFs, such as in-kind redemption and staking, are also likely. 'I think we will see the vast majority, if not all, of the currently filed 19b-4s obtain approval by the end of the year,' Seyffart told Investopedia. 'That includes in-kind [redemptions] and staking and something like 10 individual assets [that have] attempted to get an ETF.' Additionally, the undeniable success of the IPO for stablecoin issuer Circle (CRCL) has not gone unnoticed. Galaxy (GLXY) and eToro (ETOR), which are both heavily involved in the crypto market, also debuted earlier this year. According to Nate Geraci, President of The ETF Store, there could be more IPOs on the way from the likes of crypto exchanges Gemini and Kraken, and blockchain technology companies Consensys and Ripple, among others. Finally, ether (ETHUSD), the native cryptocurrency of the Ethereum blockchain and long the second-largest crypto asset behind bitcoin, may also be at a critical point in its history. It has underperformed both bitcoin and some of its smaller competitors, such as Binance Smart Chain and Solana, in recent years. A recent report from a group of Ethereum proponents gained attention for comparing ether to digital oil. Still, some investors doubt that the use of Ethereum's tech by the likes of Coinbase Global (COIN) and stablecoin-issuers will necessarily accrue value to the ether asset itself over the long term. That said, Lawant believes there are still plenty of reasons to not count out ether quite yet. 'There have been clear signs over the past few months that sentiment is shifting in the Ethereum ecosystem,' said Lawant. 'Ethereum also benefits from being more closely tied to traditional capital markets, which is a key price driver in today's environment. That's evident in its active CME futures market and the launch of spot ETFs." Ether "also remains underowned by many institutional investors," says Lawant. Analysts say the addition of staking to spot ether ETFs could help improve institutional adoption. "If the current developments play out as expected, there's meaningful room for a catch-up.' Ether is down about 85% relative to bitcoin since hitting an all-time high of 0.1475 ether per bitcoin roughly eight years ago, according to data from CoinGecko. Read the original article on Investopedia Sign in to access your portfolio
